Clinical Report: Links Between FGF23 and Apelin-13 Levels with Osteoporosis

Overview

This study investigates the relationships between FGF23, Apelin-13, osteoporosis (OP), and diabetic peripheral neuropathy (DPN) in postmenopausal women with type 2 diabetes mellitus (T2DM). Key findings indicate that FGF23 and Apelin-13 levels are independently associated with bone mineral density and the risk of OP and DPN.

Background

Type 2 diabetes mellitus significantly increases the risk of complications such as osteoporosis and diabetic peripheral neuropathy, particularly in postmenopausal women. Understanding the interplay between metabolic factors like FGF23 and Apelin-13 is crucial for developing effective prevention and treatment strategies for these conditions. Current diagnostic methods may not adequately capture the complexities of bone health in this population.

Data Highlights

Key Findings

• FGF23 levels were independently associated with lower T-scores, indicating higher OP risk.
• Apelin-13 levels were independently associated with higher T-scores, indicating protective effects against OP.
• Longer diabetes duration and elevated CPT scores correlated with increased OP risk.
• Combined predictive model of DD, E2, CPT, FGF23, and Apelin-13 showed high discrimination for OP (AUC = 0.958).
• Lower BMD T-scores were linked to increased DPN risk (OR = 0.13, p < 0.001).

Clinical Implications

Healthcare providers should consider monitoring FGF23 and Apelin-13 levels in postmenopausal women with T2DM to better assess osteoporosis and diabetic peripheral neuropathy risk. The findings suggest potential avenues for targeted interventions aimed at these biomarkers to improve patient outcomes.

Conclusion

The study highlights the significant role of FGF23 and Apelin-13 in the context of osteoporosis and diabetic peripheral neuropathy among postmenopausal women with type 2 diabetes. Further research is warranted to validate these findings and explore therapeutic implications.

Related Resources & Content

1. Author(s)/Org, Source, Year -- F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes
2. Author(s)/Org, Source, Year -- Bone Microstructure in Elderly Men with Type 2 Diabetes: Significance of Bone Dimensions
3. Author(s)/Org, Source, Year -- Changes in Bone Health Observed in Adolescent Girls With Type 1 Diabetes Before Clinical Neuropathy Manifestation
4. Author(s)/Org, Source, Year -- The Individual and Synergistic Impact of GIP, GLP-1, and GLP-2 on Bone Turnover Biomarkers in Individuals with Type 2 Diabetes
5. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
6. Recommendation: Osteoporosis to Prevent Fractures: Screening | United States Preventive Services Taskforce
7. ADA’s Standards of Care in Diabetes—2026
8. Osteoporosis Screening Recommendations